The microbiome, carcinogenesis, and prognosis: Driver or passenger?

ESGO eAcademy, Julien Marchesi, 282848

Splenectomy, distal pancreatectomy, and partial gastrectomy

ESGO eAcademy, Pawel Knapp, 282853

The vaginal microbiome, HPV infection, and progression of cervical disease

ESGO eAcademy, Murat Gultekin, 282847

Assessment of resectability: Imaging and/or laparoscopy

ESGO eAcademy, Fagotti Anna, 282851

Carcinogenesis and prognosis in gynaecological cancers: Is this microbiome-related?

ESGO eAcademy, Maria Kyrgiou, 282846

Case presentation of foetal and neonatal follow-up during and after chemo during pregnancy

ESGO eAcademy, Monica Fumagalli, 282843

Adding translational research in Gyn Cancer trials

ESGO eAcademy, Sandro Pignata, 282838

Case presentation of cervical cancer during pregnancy

ESGO eAcademy, Frederic Amant, 282842

Innovation in endometrial cancer and cervical cancer

ESGO eAcademy, Antonio Gonzalez-Martin, 282837

Innovation in ovarian cancer

ESGO eAcademy, Isabelle Ray-Coquard, 282836

Case presentation of breast cancer during pregnancy

ESGO eAcademy, Michael Halaska, 282841

Advances in techniques for external beam radiotherapy and brachytherapy in cervical cancer

ESGO eAcademy, Jacob Lindegaard, 282833

The way forward: Novel agents in development

ESGO eAcademy, Rosalind Glasspool, 282828

Achieving better local control with less toxicity through evidence-based planning aims and dose volume constraints

ESGO eAcademy, Christian Kirisits, 282832

Novel targets: A molecular perspective

ESGO eAcademy, Viola Heinzelmann-Schwarz, 282827

Parallel session 21: Platinum-resistant ovarian cancer: A new definition and novel approaches in a changing landscape

ESGO eAcademy, Antonio Gonzalez-Martin, 282825

Radiotherapy in cervical cancer, where do we come from? Where are we now? Where are we going?

ESGO eAcademy, Elzbieta van der Steen-Banasik, 282831

Sex cord stromal tumours in adolescents

ESGO eAcademy, Dominik Schneider, 282818

The role of immunotherapy in GTN

ESGO eAcademy, Ulrika Joneborg, 282823

Germ cell tumours in adolescents

ESGO eAcademy, Philippe Morice, 282817

How to manage placental site nodules, PSTT, and ETT

ESGO eAcademy, Michael Seckl, 282822

Specificities of treating cancers in adolescents

ESGO eAcademy, Gabriele Calaminus, 282816

The key ingredients for a successful GTD centre

ESGO eAcademy, Christianne Lok, 282821

Systemic molecular targeted therapies: Achievements and prospects

ESGO eAcademy, Jonathan Ledermann, 282807

Novel combinations in ovarian cancer

ESGO eAcademy, Johanna Maenpaa, 282813

MRI Guided Brachytherapy: Evolution and challenges

ESGO eAcademy, Johannes Dimopoulos, 282806

Novel targeted drugs in endometrial cancer

ESGO eAcademy, Faculty / Presenters, 282812

Technological developments in surgery and the contribution of robotic surgery

ESGO eAcademy, Rainer Kimmig, 282805

Emerging targeted therapies in cervical cancer

ESGO eAcademy, Ana Oaknin, 282811

Vaccination: Achievements and challenges

ESGO eAcademy, Elmar Joura, 282804

DNA repair interfering therapies

ESGO eAcademy, Nicole Concin, 282810

Introduction Uzi Beller Award

ESGO eAcademy, Pedro Ramirez, 282799

Best translational research - Helga Salvesen Award

ESGO eAcademy, George Coukos, 282798

Introduction Helga Salvesen award

ESGO eAcademy, Cristiana Sessa, 282797

The role of immunotherapy in the management of gynecological cancers

ESGO eAcademy, Meletios Dimopoulos, 282796

Is the new endometrial cancer classification ready for prime time?

ESGO eAcademy, Carien Creutzberg, 282794

Is there a role for immunotherapy in endometrial cancer?

ESGO eAcademy, Sandro Pignata, 282793

Is cytoreduction an option in advanced endometrial cancer

ESGO eAcademy, Elena Ulrikh, 282792

Chemotherapy in advanced endometrial cancer

ESGO eAcademy, Aristotelis Bamias, 282791

Trophoblastic diseases

ESGO eAcademy, Michael Seckl, 290423

Ovarian clear cell carcinoma

ESGO eAcademy, Antonio Gonzalez-Martin, 290422

Mucinous carcinoma

ESGO eAcademy, Jonathan Ledermann, 290421

Cancerized teratoma

ESGO eAcademy, Rosalind Glasspool, 290420

Uterine LMS

ESGO eAcademy, Jae-Weon Kim, 290419

Radiotherapy in the elderly

ESGO eAcademy, Elzbieta van der Steen-Banasik, 282786

State of the Art 7: ESGO-GCIG Rare Tumours Guidelines

ESGO eAcademy, Isabelle Ray-Coquard, 282788

Medical treatment of elderly women with gynaecological cancers: Strategies for a heterogeneous population

ESGO eAcademy, Annamaria Ferrero, 282785

Pre-and postoperative evaluation, morbidity and postoperative outcome of elderly cancer patients

ESGO eAcademy, Dina Kurdiani, 282784

Sex cord tumour

ESGO eAcademy, Isabelle Ray-Coquard, 290425

Low grade serous carcinoma

ESGO eAcademy, Gourley Charlie, 290424

Uterine Carcinosarcomas

ESGO eAcademy, Ronnie Shapira-Frommer, 290418

Ovarian small cell carcinoma

ESGO eAcademy, Clare Scott, 290417

Germ Cell tumour

ESGO eAcademy, Nicoletta Colombo, 290416

Genetic testing: The patient's perspective (patient rep from ENGAGE)

ESGO eAcademy, Birthe Lemley, 282781

Management of Lymph Nodes in Ovarian Cancer

ESGO eAcademy, Philipp Harter, 285950

Genetic counselling for Lynch syndrome in gynaecological cancers

ESGO eAcademy, Pawel Blecharz, 282780

Relevance of lymphadenectomy in cervical cancer in the SLN era

ESGO eAcademy, Fabrice Lecuru, 282775

BRCA mutations: Implications for the patient and family

ESGO eAcademy, Emmanouil Saloustros, 282779

Remaining indications for lymphadenectomy in ovarian cancer

ESGO eAcademy, Nicole Concin, 282774

Parallel session 13: Genetic testing and counselling in gynaecological cancers: Which patients, how, and by whom?

ESGO eAcademy, Banerjee Susana, 282777

Current role of pelvic and aortic lymphadenopathy in endometrial cancer

ESGO eAcademy, Nadeem R. Abu-Rustum, 282773

A look at da Vinci robotic-assisted surgery postoperative results

ESGO eAcademy, Celine Lonnerfors, 282770

The place of da Vinci robotic-assisted surgery in an Enhanced Recovery program

ESGO eAcademy, Eric Lambaudie, 282769

Vulvar cancer

ESGO eAcademy, Ate Van Der Zee, 282767

Endometrial cancer

ESGO eAcademy, Nadeem R. Abu-Rustum, 282766

ESGO meta-analysis for triage of HPV-positive cases

ESGO eAcademy, Marc Arbyn, 282760

Cervical cancer

ESGO eAcademy, David Cibula, 282765

Up-to-date in cervical cancer screening: ESGO-EFC joint statement

ESGO eAcademy, Jack Cuzick, 282759

SLN ultrastaging

ESGO eAcademy, Glenn McCluggage, 282764

State of the art in HPV vaccination: ESGO-EFC joint statement

ESGO eAcademy, Elmar Joura, 282758

State of the Art 5: ESGO-EFC new recommendations on prevention

ESGO eAcademy, Murat Gultekin, 282757

Enhanced Recovery Hospital Implementation Process (ERAS): A holistic approach

ESGO eAcademy, Pedro Ramirez, 282756

Perspectives in novel treatments

ESGO eAcademy, Domenica Lorusso, 282750

Pre- and postoperative care: Focussing on nutrition and immunonutrition

ESGO eAcademy, Annamaria Ferrero, 282755

Is there a role for radiotherapy in high-risk early-stage disease?

ESGO eAcademy, Carien Creutzberg, 282749

Perioperative anaesthetic management

ESGO eAcademy, Carolyn Weiniger, 282754

Is there a role for chemotherapy in high-risk early-stage disease?

ESGO eAcademy, Faculty / Presenters, 282748

The role of the Intensive Care Unit (ICU) in postoperative management

ESGO eAcademy, Nikolaos Thomakos, 282753

Endometrial cancer: A single disease?

ESGO eAcademy, Tjalling Bosse, 282747

Presidential lecture

ESGO eAcademy, Denis Querleu, 282744

Surgical performance

ESGO eAcademy, Karl Tamussino, 282742

QI related to patients´ management

ESGO eAcademy, Francesco Raspagliesi, 282741

How to develop and how to use QI

ESGO eAcademy, David Cibula, 282740

Lessons learned: EWOC-1/EORTC55944/ PORTEC-3*

ESGO eAcademy, Nicoletta Colombo, 282737

First line ovarian cancer trials: VELIA/Forward1

ESGO eAcademy, Faculty / Presenters, 282736

PARP combination studies: PRIMA/PAOLO-1/ANVANOVA2

ESGO eAcademy, Jonathan Ledermann, 282735

CON: open radical hysterectomy should be the new standard of care

ESGO eAcademy, Pedro Ramirez, 282728

PRO: Minimally invasive radical hysterectomy should remain the standard approach

ESGO eAcademy, Henrik Falconer, 282727

Discussion

ESGO eAcademy, Nadeem R. Abu-Rustum, 286497

Development and validation of an endometrial carcinoma preoperative Bayesian network using molecular and clinical biomarkers (ENDORISK): an ENITEC collaboration study

ESGO eAcademy, Casper Reijnen, 286495

Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial

ESGO eAcademy, Alicia Leon-Castillo, 286496

Lympho-vascular space invasion is strongly associated with lymph node metastases and decreased survival in endometrioid endometrial cancer: a Swedish Gynecologic Cancer Group (SweGCG) study

ESGO eAcademy, Karin Stalberg, 286494

Conservative treatment of atypical endometrial hyperplasia and early endometrial cancer: a prospective single institution study of 418 patients

ESGO eAcademy, Olga Novikova, 286493

Quality assurance in ovarian cancer surgery

ESGO eAcademy, Andreas du Bois, 282724

Update on chemotherapy and targeted therapy of high-grade serous carcinomas

ESGO eAcademy, Nicoletta Colombo, 282719

Quality assurance in endometrial cancer surgery

ESGO eAcademy, Jan Persson, 282723

Surgical management of early, advanced, and recurrent adnexal carcinomas

ESGO eAcademy, Denis Querleu, 282718

Quality assurance in cervical cancer surgery

ESGO eAcademy, Andreas Obermair, 282722

Pathology and pathologic markers of extra-uterine high-grade serous carcinoma

ESGO eAcademy, Glenn McCluggage, 282717

Laparoscopic scores to predict operability: Are they sufficient to stratify patients safely into surgical pathways?

ESGO eAcademy, Giovanni Scambia, 282708